LSK NRDO Co., Ltd. (President Young Jack Lee) established by LSK Global Pharma Services Co., Ltd.(LSK Global PS, President Young Jack Lee) to be specialized in new drug development announced it had signed an agreement for the transfer of patent and technology on ‘DGG-200338’, a solid tumor treatment candidate with Dongguk University Industry Academy Cooperation Foundation on March 7, 2019.

Under this agreement, LSK NRDO will take over the patent on DGG-200338 from Dongguk University Industry Academy Cooperation Foundation and has planned to conduct chemistry, manufacturing, and control (CMC) and nonclinical trials, and complete phase 1 clinical trial for solid tumors by 2021. LSK NRDO Co. has also planned to expand the drug’s indications to various cancers including colon cancer and will consider licensing it out depending on the outcomes.

DGG-200338 which is the first pipeline of LSK NRDO is an innovative new drug targeting solid cancers and has been recognized for its value as a new drug due to its action mechanism differentiated from conventional anticancer drugs and confirmed potential to be developed as an oral anticancer drug. Its excellent anticancer effects in solid tumors such as colon, lung, renal, and skin cancers were demonstrated in in vitro efficacy tests. It was also confirmed through an in vivo efficacy test that DGG-200338 inhibited the tumor volume by about 90%. In addition, DGG-200338 was shown to have excellent anticancer effects against the resistant cell lines of commercial anticancer drugs and is expected to provide various treatment option to the patients resistant to existing anticancer drugs.

The agreement for the patent transfer between LSK NRDO and Dongguk University Industry Academy Cooperation Foundation is the first business of LSK NRDO. LSK NRDO is a subsidiary of LSK Global PS established in last February to actively construct a pipeline for new drugs based on the No Research Development Only (NRDO) model.

LSK Global PS has prepared for the full-fledged NRDO business over the past few years through the risk-sharing investments in bio-venture companies with a plan to present a new success model for domestic CRO business via establishment of LSK NRDO. LSK NRDO possesses competitiveness for faster and more efficient operations than pharmaceutical companies and other NRDO institutions by utilizing all the know-how, and human and physical infrastructures LSK Global PS has accumulated through its experience in conducting clinical researches for 20 years as a leading CRO in Korea.